Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
BV + pembrolizumab in solid tumor malignancies resulted in clinically meaningful, durable responses with encouraging OS and PFS rates supportive of the immunomodulatory activity of this combination. Stronger antitumor activity was observed in secondary refractory cohorts. The safety profile of this combination was consistent with the individual drug risk profiles.
Authors
- Inderjit Mehmi (ORCID: https://orcid.org/0000-0002-2253-2206)
- Hailing Lu (ORCID: https://orcid.org/0000-0002-6418-9688)
- Omid Hamid (ORCID: https://orcid.org/0000-0002-8238-4655)
- Theresa Michelle Medina (ORCID: https://orcid.org/0000-0003-0579-4121)
- Marya Chaney (ORCID: https://orcid.org/0000-0001-6820-7081)
- Sunandana Chandra (ORCID: https://orcid.org/0000-0001-7936-5069)
- Brian P. O’Connor (ORCID: https://orcid.org/0000-0002-4776-2622)
- Charles Lance Cowey (ORCID: https://orcid.org/0000-0002-9726-5309)
- Graham Watson
- Robert M. Jotte (ORCID: https://orcid.org/0000-0003-3920-0731)
- Yousef Zakharia (ORCID: https://orcid.org/0000-0001-9480-2626)
- Jason D. Berndt (ORCID: https://orcid.org/0000-0002-7388-6792)
- Amanda Gillespie-Twardy
- Patrick J. Ward (ORCID: https://orcid.org/0000-0002-7800-4840)
- Sylvia M. Lee (ORCID: https://orcid.org/0000-0002-7425-2230)
- Kapil Rathi (ORCID: https://orcid.org/0009-0004-1606-5666)
- Eeman Shaikh
Institutions
- Northwestern University (US)
- University of Iowa (US)
- Cedars-Sinai Medical Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Midwestern University (US)
- Baylor University (US)
- Pfizer (United States) (US)
- University of Washington (US)
- Texas Oncology (US)
- Carilion Roanoke Memorial Hospital (US)
- University of Iowa Hospitals and Clinics (US)
- Baylor University Medical Center (US)
- Virginia Oncology Associates (US)
- Fred Hutch Cancer Center (US)
- Mountain Blue Cancer Care Center (US)
- Angeles Clinic and Research Institute (US)
- Merck Institute for Science Education (US)
- University of Colorado Cancer Center (US)
- University of Washington Bothell (US)
- Rocky Mountain Cancer Centers (US)
- The US Oncology Network (US)
- Oncology Hematology Care (US)
- Iowa City Public Library (US)
- Metis Design Corporation (United States) (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1478
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Bristol-Myers Squibb
- Pfizer
- Exelixis
- Moderna
- Seagen
- Eisai
- Genentech
- Janssen Research and Development